Recently, the Senate Committee on Health, Education, Labor and Pensions (HELP) introduced a discussion draft that included guidelines to educate patients and providers about biosimilars.
The Biosimilars Forum issued the following statement in response:
“The Biosimilars Forum commends the Senate HELP Committee for including language that would direct the FDA to close the education gap and expel misinformation about biosimilars for both patients and providers. Misinformation and a lack of understanding about lower-cost biosimilars is threatening patients’ access to these life-saving therapies and costing the U.S. billions in untapped savings throughout the health care system. Education is critical, but more needs to be done to increase usage of these lower cost alternatives. We look forward to working with the Senate to educate and help unlock the benefits of these equally-safe and effective therapies.”
To learn more about The Biosimilars Forum, click here (http://biosimilarsforum.org/).